Profusa Receives ISO 13485:2016 Certificate from GMED

Profusa secures ISO 13485:2016 certification, advancing its Lumee Oxygen Platform toward EU market entry.

What the company is saying

Profusa, Inc. (NASDAQ:PFSA) announces receipt of its ISO 13485:2016 certificate from GMED, covering the design, development, and manufacture of the Lumee Oxygen Platform at its Berkeley, California facility. The company frames this as a critical regulatory milestone, emphasizing that ISO 13485 certification is foundational for ongoing MDR conformity assessment and a prerequisite for CE marking and European commercial distribution. Profusa highlights that this certification is independently audited and aligns with both EU and updated U.S. FDA quality management standards, reinforcing its credibility for potential partners and customers. The announcement states that manufacturing of the Lumee Oxygen Sensor Platform can now begin, but does not provide operational or production figures. President Ben Hwang, Ph.D., is quoted positioning the certification as a key enabler for the next regulatory steps and future commercialization in Europe. The company also references a previously signed Option Agreement for a potential acquisition of G3 Vision Labs, Inc., but clarifies that exercising this option is not obligatory and is subject to conditions.

What the data suggests

The ISO 13485:2016 certificate was received on October 15, 2026, following a positive certification decision on September 24, 2026. The certification scope includes the Lumee Oxygen tissue-integrated biosensors and associated readers, with all design, development, and manufacturing activities based in Berkeley, California. ISO 13485 is the internationally recognized standard for medical device quality management systems and is now incorporated into the FDA's Quality Management System Regulation (QMSR) effective February 2, 2026. While the announcement confirms the certification, it does not disclose any financial data, production volumes, or operational milestones beyond the regulatory achievement. The company states it can now begin manufacturing but provides no evidence that manufacturing has started or at what scale. The MDR conformity assessment process for CE marking remains ongoing, with no timeline or probability of success disclosed. The Option Agreement for G3 Vision Labs, Inc. is mentioned as a future possibility, with no financial or operational details provided. Overall, the data confirms a regulatory milestone but leaves commercial, operational, and financial impacts unquantified.

Analysis

The announcement is positive in tone, highlighting the achievement of ISO 13485:2016 certification, which is a meaningful regulatory milestone for Profusa, Inc. This is a realised, independently-audited event and supports the company's ongoing MDR conformity assessment for its Lumee Oxygen Platform. However, the announcement also contains several forward-looking statements regarding future MDR certification, CE marking, commercial distribution in the EU, and a potential acquisition, none of which are yet realised. No financial, operational, or profitability metrics are disclosed, so the investment impact cannot be fully assessed. The language is generally proportionate to the milestone, but some claims about future commercialisation and acquisition outcomes are speculative. The gap between narrative and evidence is moderate: the ISO certification is real, but the commercial and financial benefits remain unquantified and contingent on further regulatory approvals.

Risk flags

• ●The path to CE marking and EU commercial distribution remains incomplete, as MDR conformity assessment activities are still ongoing with no stated timeline or probability of success. This regulatory uncertainty could delay or prevent market entry.
• ●No operational, production, or financial metrics are disclosed following certification, so the actual readiness for manufacturing scale-up and commercial sales is unproven. The absence of quantifiable data limits visibility into near-term revenue or margin impact.
• ●The Option Agreement to acquire G3 Vision Labs, Inc. is non-binding and subject to unspecified conditions, introducing uncertainty about future business structure and potential integration risks if the option is exercised.
• ●While ISO 13485:2016 certification aligns with FDA QMSR requirements, it does not constitute FDA clearance or approval, so U.S. market access for the Lumee Oxygen Platform remains subject to additional regulatory hurdles.

Bottom line

Profusa's ISO 13485:2016 certification is a necessary regulatory step for its Lumee Oxygen Platform, enabling the company to proceed with manufacturing and supporting its ongoing MDR conformity assessment for future EU market access. The announcement is credible as a regulatory update, but provides no operational or financial details to assess commercial readiness or revenue impact. The timeline to value remains uncertain, as CE marking and EU distribution are contingent on further regulatory approvals with no disclosed deadlines. The Option Agreement for a potential G3 Vision Labs, Inc. acquisition is speculative and does not affect near-term fundamentals. Investors should focus on evidence of manufacturing scale-up, progress toward MDR certification and CE marking, and disclosure of commercial traction or financial metrics in future updates. The key takeaway is that Profusa has cleared an important regulatory hurdle, but the commercial and financial implications are still to be demonstrated.

Announcement summary

(NASDAQ:PFSA) Profusa, Inc. announced it has received its ISO 13485:2016 certificate from GMED, a notified body designated under the European Union Medical Device Regulation (MDR). The certificate covers the design, development, and manufacture of the Lumee Oxygen tissue-integrated biosensors and associated readers (the Lumee Oxygen Platform) at Profusa's Berkeley, California facility. The ISO 13485:2016 certification follows a positive certification decision announced by Profusa on September 24, 2026. ISO 13485 is an internationally recognized standard for medical device quality management systems, and certification demonstrates, through independent audit, that Profusa's quality management system conforms to the applicable requirements of ISO 13485:2016 within the scope of certification. This certification supports Profusa's ongoing MDR conformity assessment activities for the Lumee Oxygen Platform and is commonly expected of medical device suppliers during European hospital procurement and distributor qualification processes. CE marking would indicate conformity with applicable EU MDR requirements and would permit Profusa to pursue commercial distribution in the European Union, subject to satisfying applicable regulatory and operational requirements. Profusa continues to work with GMED to complete the remaining MDR conformity assessment activities for the Lumee Oxygen Platform, which, if successfully completed, would support issuance of the MDR certificate and CE marking. With the ISO certificate, Profusa can now begin manufacturing the Lumee Oxygen Sensor Platform. In the United States, FDA's Quality Management System Regulation (QMSR), effective February 2, 2026, incorporates ISO 13485:2016 by reference. While ISO 13485 certification does not constitute FDA clearance or approval, it demonstrates conformity with a quality management system standard incorporated into FDA's updated regulatory framework. Ben Hwang, Ph.D., President of Profusa, stated that obtaining ISO 13485 certification provides independent confirmation of Profusa's quality management system and is an important foundation as the company continues working toward completion of MDR conformity assessment activities, obtaining MDR certification and CE marking, and preparing for future commercialization in Europe. Profusa previously announced the signing of an Option Agreement which provides Profusa the right and option, but not the obligation, subject to satisfaction of certain conditions, to acquire G3 Vision Labs, Inc. and its subsidiaries. Upon option exercising, the combined company is expected to operate as a public diagnostics company. “LUMEE”, “PROFUSA” and the PROFUSA logo are registered trademarks of Profusa, Inc. in the United States, Canada, European Union, China, Japan, South Korea, and Australia.

Disagree with this article?